TrialESMO open2025

Regorafenib combined with irinotecan as second-line treatment in metastatic gastro-oesophageal adenocarcinomas: results of PRODIGE 58-UCGI35-REGIRI Unicancer randomised phase II study.

E Samalin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.